Trial Profile
ATG Fresenius observational study on the prevention of GvHD in allogeneic stem cell transplant patients - ATOS
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2020
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary) ; Methotrexate (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms ATOS
- Sponsors Neovii Biotech
- 14 Feb 2013 New trial record